Uppsala, Sweden, 2013-06-13 14:29 CEST (GLOBE NEWSWIRE) --
Mikael has an extensive experience of communications from the international pharmaceutical industry, AstraZeneca and Biovitrum among others, and from investment companies such as Nordic Capital. The employment begins on July 22.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: email@example.com Phone: +46 (0) 18 50 54 40. www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia